1,2,6-trimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid-5-carboxylic acid ethyl ester | 50899-12-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1,2,6-trimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid-5-carboxylic acid ethyl ester
• 英文别名: 5-ethoxycarbonyl-1,2,6-trimethyl-4-(3-nitrophenyl)-4H-pyridine-3-carboxylic acid
• CAS: 50899-12-2
• 化学式: C₁₈H₂₀N₂O₆
• 分子量: 360.367
• InChiKey: CHQDYWOZVXNKCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1,2,6-trimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid-5-carboxylic acid ethyl ester 、 N,N-二甲基-3-氯丙胺 在 sodium 作用下， 以 乙醇 为溶剂， 生成 1,2,6-Trimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(γ-dimethylamino)-propyl ester 5-ethyl ester
  参考文献：
  名称：

  1,4-Dihydropyridine carboxylic acid esters useful as coronary vessel

  摘要：

  某些1,4-二氢吡啶羧酸酯或其药用上可接受的无毒盐可用作冠状动脉扩张剂和降压药。

  公开号：

  US03974275A1

文献信息

• MEDICINAL COMPOSITION, PROCESS FOR PRODUCING THE SAME, AND METHOD OF STABILIZING DIHYDROPYRIDINE COMPOUND IN MEDICINAL COMPOSITION
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1813274A1

  公开（公告）日：2007-08-01

  The present invention aims to provide a pharmaceutical composition containing a stable dihydropyridine compound, where improving the stability of dihydropyridine compounds in pharmaceutical compositions under influence of storage conditions and thus providing a pharmaceutical composition with superior handling ability and affordable administration. As such, the present invention is a pharmaceutical composition, comprising a dihydropyridine compound, and at least one selected from iron oxide and carrageenan; and a method for producing a pharmaceutical composition. In addition, the present invention is a method for stabilizing a dihydropyridine compound in a pharmaceutical composition, comprising mixing the dihydropyridine compound and at least one selected from iron oxide and carrageenan; and also a stabilizing agent, wherein the stabilizing agent is utilized for a pharmaceutical composition containing a dihydropyridine compound, and comprises at least one selected from iron oxide and carrageenan.

  本发明的目的是提供一种含有稳定的二氢吡啶化合物的药物组合物，提高药物组合物中二氢吡啶化合物在储存条件影响下的稳定性，从而提供一种处理能力更强、用药更经济的药物组合物。 因此，本发明是一种药物组合物，包括二氢吡啶化合物以及至少一种选自氧化铁和卡拉胶的化合物；以及一种生产药物组合物的方法。此外，本发明是一种稳定药物组合物中二氢吡啶化合物的方法，包括混合二氢吡啶化合物和至少一种选自氧化铁和卡拉胶的物质；以及一种稳定剂，其中稳定剂用于含有二氢吡啶化合物的药物组合物，并包括至少一种选自氧化铁和卡拉胶的物质。
• Method for treating a demyelinating condition
  申请人：——

  公开号：US20030055036A1

  公开（公告）日：2003-03-20

  Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca 2+ -channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca 2+ -channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca 2+ -channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca 2+ -channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier. Additionally, pharmaceutical compositions having a Ca 2+ -channel blocker, a hypertensive agent, and a pharmaceutically-acceptable carrier are provided.

  本文提供了治疗需要治疗的受试者脱髓鞘病症的方法。在某些方面，这些方法包括向受试者施用一定量的 Ca 2&plus； -通道阻滞剂有效治疗脱髓鞘病症。在其他方面，这些方法包括向受试者施用有效治疗脱髓鞘病症的谷氨酸抑制剂。在其他方面，这些方法包括向受试者施用 Ca 2&plus； -通道阻滞剂与谷氨酸抑制剂联合使用，其用量对治疗脱髓鞘病症有效。还在其他方面，这些方法包括向受试者施用 Ca 2&plus； -通道阻滞剂与高血压药联合使用，其用量对治疗脱髓鞘病症有效。还提供了具有 Ca 2&plus； -通道阻滞剂、谷氨酸抑制剂和药学上可接受的载体的药物组合物。此外，还提供了具有 Ca 2&plus； -通道阻滞剂、高血压药和药学上可接受的载体的药物组合物。
• JPS6341459A
  申请人：——

  公开号：JPS6341459A

  公开（公告）日：1988-02-22
• Pharmaceutical Composition, Method for Producing the Same, and Method for Stabilizing Dihydropyridine Compound in the Pharmaceutical Composition
  申请人：Suzuki Toshio

  公开号：US20080095841A1

  公开（公告）日：2008-04-24

  The present invention aims to provide a pharmaceutical composition containing a stable dihydropyridine compound, where improving the stability of dihydropyridine compounds in pharmaceutical compositions under influence of storage conditions and thus providing a pharmaceutical composition with superior handling ability and affordable administration. As such, the present invention is a pharmaceutical composition, comprising a dihydropyridine compound, and at least one selected from iron oxide and carrageenan; and a method for producing a pharmaceutical composition. In addition, the present invention is a method for stabilizing a dihydropyridine compound in a pharmaceutical composition, comprising mixing the dihydropyridine compound and at least one selected from iron oxide and carrageenan; and also a stabilizing agent, wherein the stabilizing agent is utilized for a pharmaceutical composition containing a dihydropyridine compound, and comprises at least one selected from iron oxide and carrageenan.
• US3974275A
  申请人：——

  公开号：US3974275A

  公开（公告）日：1976-08-10